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Differential Effects of the Hormonal 
and Copper Intrauterine Device on 
the Endometrial Transcriptome
Karen Smith-Mccune  1 ✉, Reuben thomas2, Sarah Averbach1,3, Dominika Seidman1, 
Margaret Takeda1, Sahar Houshdaran1 & Linda C. Giudice1
The contraceptive effectiveness of intrauterine devices (IUDs) has been attributed in part to a foreign 
body reaction in the endometrium. We performed this study to better understand mechanisms of action 
of contraceptives of by studying their effects on endometrial and cervical transcriptomes. We collected 
endometrial and cervical biopsies from women using the levonorgestrel-releasing intrauterine system 
(LNG-IUS, n = 11), copper intrauterine device (cu-IUD, n = 13) or levonorgestrel-containing combined 
oral contraceptives (COC, n = 12), and from women not using contraceptives (control group, n = 11). 
Transcriptional profiling was performed with Affymetrix arrays, Principal Component Analysis and the 
bioconductor package limma. In endometrial samples from cu-IUD users, there were no genes with 
statistically significant differential expression compared to controls. In LNG-IUS users, 2509 genes were 
differentially expressed and mapped predominantly onto immune and inflammatory pathways. The 
cervical samples showed no statistically significant differential gene expression compared to controls. 
Hormonal and copper IUDs have significantly different effects on the endometrial transcriptome, with 
the LNG-IUS transcriptome showing pronounced inflammation and immune activation compared to 
controls whereas the cu-IUD transcriptome was indistinguishable from luteal phase endometrium. 
These findings argue against a foreign body reaction as a common mechanism of action of IUDs.
The intrauterine device (IUD) is a popular and effective form of contraception used by approximately 14% of 
women globally1. Commonly used IUDs include a hormonal IUD that releases levonorgestrel (LNG-IUS), and 
a non-hormonal copper IUD (cu-IUD) that releases copper ions. The contraceptive efficacy of IUDs has been 
attributed in part to their effects as foreign bodies that induce local inflammation; in addition, the cu-IUD and 
LNG-IUS have direct toxic effects on sperm and the LNG-IUS also causes endometrial atrophy and alterations in 
cervical mucus rendering it unfavorable to sperm penetration2–5.
We recently studied the local immune microenvironment in the upper female reproductive tract of LNG-IUS 
users compared to mid-luteal samples from women not using hormonal or intrauterine contraceptives6,7. We 
found that the endometrial transcriptome from LNG-IUS users was associated with pronounced signals of 
inflammation consistent with a foreign body reaction7. These findings could be due to the presence of a foreign 
body (the IUD), the effect of LNG released by the IUD, or both. The purpose of this study was to compare the 
independent and combined effects of LNG exposure and IUD exposure on the transcriptome of the upper female 
reproductive tract, in order to better understand potential mechanisms of contraceptive action by these different 
methods.
Methods
Study design. This was a cross-sectional study comparing transcriptomes from the endometrium or cervi-
cal transformation zone (TZ) from samples donated by 4 groups of women using: no hormonal or intrauterine 
contraception (controls), cu-IUD (Paragard T 380 A, Cooper Surgical, Trumbull CT), LNG-IUS (Mirena, Bayer 
Healthcare Pharmaceuticals Inc, Finland) or LNG-containing COC. The UCSF Human Research Protection 
Program & IRB approved the study protocol, recruiting and consent materials; all procedures were performed in 
accordance with these regulations.
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Study procedures. Methods for the recruitment, screening and sample collection are described in detail 
elsewhere8; participants whose samples contributed to this study had sufficient amounts of appropriate endo-
metrial and/or cervical tissue. Briefly, healthy women volunteers age 18–45 years were recruited from the San 
Francisco Bay Area. Participants in the COC group had to be using a cyclic 28-day pill pack of ethinyl estrogen 
plus LNG containing either 0.10 or 0.15 mg of LNG per tablet. Participants in the control and cu-IUD groups had 
to have regular periods every 21–35 days. Exclusion criteria included hysterectomy, breast-feeding, being within 
6 months of parturition, having abnormal cervical cytology in the past year, and use of systemic corticosteroids 
or immune‐modulating therapies. At the screening visit, written informed consent was obtained from all partic-
ipants, urine was tested for pregnancy, Chlamydia trachomatis and Neisseria gonorrheae, and blood was tested 
for HIV serology; a positive result or clinical evidence of vaginitis, vaginosis or pelvic inflammatory disease 
resulted in exclusion. At the second study visit, participants were given kits and instructions for urine testing for 
luteinizing hormone (LH) (ClearBlue Ovulation Test Digital, Proctor and Gamble, Cincinnati, OH). Women in 
the control and cu-IUD groups underwent biopsies 7 to 11 days after a positive LH test result. Women using the 
LNG-IUS underwent biopsies 7 to 11 days after a positive LH test or at their convenience after 2 months with no 
positive result, whichever came first. COC users underwent biopsies on day 12–16 of their pill pack.
For sample collection, the posterior vaginal fornix was swabbed with Q-tips for measurement of pH and 
prostate specific antigen (Abacus Diagnostics, West Hills, CA), a marker of recent vaginal intercourse; pH > 6.0 
or positive PSA test led to exclusion of the sample from analysis. Endometrial biopsy was obtained with a 3 mm 
biopsy cannula (Softflex Endometrial Biopsy Cannula, Integra Miltex, York PA) and tissue was collected with 1 
or 2 passes. A biopsy with Tischler forceps was performed at the cervical TZ, identified as the junction between 
Lugol’s staining and non-staining epithelium; if the TZ was not seen, the biopsy was obtained with one of the 
biopsy prongs inside the os. Blood was collected for measurement of plasma progesterone level. Endometrial and 
cervical biopsies were snap frozen and stored at −80 degrees until analysis.
RNA Extraction and Whole Genome Microarrays. Biopsy samples were minced into small frag-
ments and total RNA was extracted and DNase-treated using the NuceloSpin RNA II Kit (Marcherey-Nagel Inc, 
Bethlehem, PA). RNA quality was assessed using Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) and 
quantity and purity determined with a NanoDrop Spectrometer. The NuGen Pico V2, based on Ribo-SPIA tech-
nology, was used for amplification, fragmentation and biotin-labelling and the labeled cDNA was hybridized to 
Human Gene 1.0 microarrays (Affymetrix, Santa Clara, CA) at the UCSF Gladstone Institutes Genomics Core. 
The signal intensity fluorescent images produced during the Affymetrix GeneChip hybridizations were read using 
the Affymetrix Model 3000 Scanner and converted into GeneChip probe results files (cel) using Command and 
Expression Console software (Affymetrix).
Gene expression data processing and statistical analysis. The analyses were performed separately 
comparing each of the contraceptive groups with the control group for the cervical and the endometrial samples. 
The raw cel files were read using the read.celfiles function that is part of the oligo package9 in bioconductor10. The 
probes were matched to their corresponding gene symbols and ensembl ids using the annotate11 and hugene10st-
transcriptcluster.db12 packages. The expression of all genes were normalized across all the samples in the chosen 
contraceptive and control group using the Robust Multi-array Average (RMA) procedure13. The top 500 most 
variable (across all samples) genes were chosen using these normalized data. The data corresponding to these 
500 genes were used to perform Principal Component Analyses (PCA) using the prcomp function in R14. The 
association of the expression of genes with the particular contraceptive use was estimated using the bioconductor 
package limma15. Due to potential confounding due to the age of the subjects, age was adjusted as a linear term in 
the (limma) models associating expression of each gene with contraceptive use. The p-values reported by limma 
are adjusted for multiple testing using the False Discovery Rate (FDR) procedure16. The raw cel files discussed 
in this publication have been deposited in NCBI’s Gene Expression Omnibus17 and are accessible through GEO 
Series accession number GSE137765.
Gene ontology and pathway analysis. The list of differentially expressed genes with adjusted p ≤ 0.05 
were entered into EnrichR, a gene list enrichment analysis tool18,19 and the Pathways analysis produced by 
Reactome 201620. The outputs displaying pathways ranked by combined score, a calculation based on the p-value 
and the Z score [log(p)•z], were chosen for presentation here.
Results
Characteristics of study participants. Table 1 demonstrates the demographic characteristics of partic-
ipants who donated endometrial samples to the study. The control group was significantly older than the IUD 
and COC users, hence the gene expression association analyses presented below are adjusted for age as described 
above. The groups did not otherwise differ with respect to race, ethnicity, education, or smoking history. For 
endometrial samples, the median progesterone level (ng/ml) in the control group was 10.8 (range 5.8–18.6) and 
in the cu-IUD group was 11.2 (5.7–27.8), confirming that the participants in these groups were in the luteal 
phase. The median progesterone level (ng/ml) in the LNG-IUS group was 3.0 (<0.5–14.3) and 4 of 11 (36%) had 
values >2 indicating ovulation. None of the participants in the COC group had measurable progesterone levels, 
consistent with the known suppression of ovulation by COCs. The median length of contraceptive exposure was 
25 (range 9–42) months for COC, 17 (7–36) months for LNG-IUS and 23 (6–45) months for cu-IUD.
Effects of contraceptives on gene expression. Principal component analysis (PCA) of each of the con-
traceptive groups compared to the control group is shown in Fig. 1. The cervical PCA plots demonstrate minimal 
differentiation between control samples and each of the contraceptive groups (Fig. 1top). In statistical analysis of 
gene expression using an adjusted p ≤ 0.05 as the threshold, no genes were significantly differentially expressed in 
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cervical samples from women using LNG-IUS, COC or cu-IUD compared to controls. The PCA plot for endome-
trial samples shows considerable sample separation for LNG-IUS versus control and is suggestive of separation 
for COC versus control (Fig. 1bottom); these comparisons are further analyzed below. For cu-IUD users, the PCA 
plot shows minimal differentiation with controls, and no genes had statistically significant differential expression 








(n = 13) P value
Age, median (min, max) 32(25,46) 24(19,33) 26(20,41) 28(22,33) 0.002*
Race, Number (%)
   Asian 1(9.1) 4(33.3) 1(9.1) 3(23.1) 0.99§
   Black/African American 5(45.4) 1(8.3) 0 0
   Other/2 or more 1(9.1) 2(16.7) 1(9.1) 1(7.7)
   Unknown 0 1(8.3) 1(9.1) 1(7.7)
   White 4(36.4) 4(33.3) 8(72.7) 8(61.5)
Ethnicity, Number (%) 0.55§
   Latino 3(27.3) 1(8.3) 3(27.3) 4(30.8)
   Non-Latino 8(72.7) 11(91.7) 8(72.7) 9(69.2)
   Unknown 0 0 0 0
Education, Number (%) 0.77§
   Some high school or college 3(27.3) 4(33.3) 3(27.3) 2(15.4)
Finished college or
   graduate school 8(72.7) 8(66.7) 8(72.7) 11(84.6)
   Smoking ever, Number (%) 3(27.3) 0 2(18.2) 1(7.7) 0.18§
Table 1. Demographic characteristics of participants who contributed endometrial samples to the study. COC 
combined oral contraceptive; LNG-IUS levonorgestrel-releasing intrauterine system; cu-IUD copper IUD.  
* ANOVA. §Fisher’s exact test.
Figure 1. Principal component analysis. After gene expression was normalized across all the samples in the 
chosen contraceptive and control group using the Robust Multi-array Average (RMA) procedure13, the data 
corresponding to the top 500 most variable genes were used to perform Principal Component Analyses (PCA) 
using the prcomp function in R14 for samples from cervix (top) and endometrium (bottom).
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Effect of LNG-IUS on endometrial gene expression. There were 2509 genes with significantly altered 
expression levels (adjusted p ≤ 0.05) in LNG-IUS users compared to control samples a; the top 50 genes are shown 






C6orf141 chromosome 6 open reading frame 141 −2.093 6.55E-09
MT1G metallothionein 1G −3.286 6.08E-08
MT1E metallothionein 1E −2.150 1.55E-07
MT1F metallothionein 1F −2.978 1.55E-07
PHYHIPL phytanoyl-CoA 2-hydroxylase interacting protein like −3.968 4.02E-07
FAM84B family with sequence similarity 84 member B −2.039 7.02E-07
CCL2 C-C motif chemokine ligand 2 3.339 7.02E-07
C9orf152 chromosome 9 open reading frame 152 −2.317 7.22E-07
CRISP3 cysteine rich secretory protein 3 −3.961 1.21E-06
CWH43 cell wall biogenesis 43 C-terminal homolog −2.371 2.19E-06
MT1M metallothionein 1M −3.446 2.40E-06
MT1H metallothionein 1H −3.299 2.40E-06
IFIT1 interferon induced protein with tetratricopeptide repeats 1 2.017 2.40E-06
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type −1.753 2.40E-06
UPK1B uroplakin 1B −3.443 4.63E-06
SLC15A1 solute carrier family 15 member 1 −3.211 4.63E-06
SLC5A1 solute carrier family 5 member 1 −1.944 4.63E-06
IFI44L interferon induced protein 44 like 3.015 4.63E-06
MT1L metallothionein 1L (gene/pseudogene) −2.688 4.63E-06
HSD17B2 hydroxysteroid 17-beta dehydrogenase 2 −1.812 5.18E-06
SLC30A2 solute carrier family 30 member 2 −1.627 6.43E-06
PLA2G16 phospholipase A2 group XVI −1.598 6.43E-06
DNAJC15 DnaJ heat shock protein family (Hsp40) member C15 −1.173 1.00E-05
MRC1 mannose receptor, C type 1 3.027 1.24E-05
MRC1 mannose receptor, C type 1 3.027 1.24E-05
HGD homogentisate 1,2-dioxygenase −3.030 1.33E-05
HGD homogentisate 1,2-dioxygenase −3.030 1.33E-05
ELMO1 engulfment and cell motility 1 1.730 1.42E-05
IL20RA interleukin 20 receptor subunit alpha −2.157 1.54E-05
GJB1 gap junction protein beta 1 −1.172 1.57E-05
FAM177A1 family with sequence similarity 177 member A1 −1.834 1.87E-05
DTNA dystrobrevin alpha 1.448 1.87E-05
MANSC1 MANSC domain containing 1 −1.469 2.01E-05
TNS1 tensin 1 1.504 2.01E-05
CLDN4 claudin 4 −1.411 2.01E-05
PLXDC2 plexin domain containing 2 1.325 2.05E-05
PLCB4 phospholipase C beta 4 −1.932 2.19E-05
TREM1 triggering receptor expressed on myeloid cells 1 3.154 2.19E-05
IGFBP1 insulin like growth factor binding protein 1 2.652 2.19E-05
IL10RA interleukin 10 receptor subunit alpha 2.022 2.53E-05
SRD5A3 steroid 5 alpha-reductase 3 −1.406 2.58E-05
FCGR2B Fc fragment of IgG receptor IIb 3.266 2.58E-05
MFSD4A major facilitator superfamily domain containing 4A −1.855 2.58E-05
TPD52L1 tumor protein D52-like 1 −2.255 2.58E-05
EPYC epiphycan 4.785 2.74E-05
MT1X metallothionein 1× −2.069 2.86E-05
TCN1 transcobalamin 1 −3.623 3.10E-05
WIPF1 WAS/WASL interacting protein family member 1 1.700 3.20E-05
MX1 MX dynamin like GTPase 1 1.798 3.29E-05
CTSL cathepsin L 2.027 3.29E-05
Table 2. Top 50 differentially expressed genes in endometrial biopsies from LNG-IUS users compared to 
controls presented hierarchically by adjusted P value.
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The Reactome pathway categories altered in LNG-IUS users are shown in Table 3 and indicate that differ-
entially expressed genes mapped predominantly onto immune and inflammatory pathways. A complete list of 
pathways that showed altered expression with a combined score (defined in section 2.5 above)>5 is shown in 
Supp Table 2.
Given that the samples in the LNG-IUS groups included a combination of those from women who had ovu-
lated and those who had not, we performed a sensitivity analysis to determine the effect of ovulatory status 
on our findings, by comparing gene expression in LNG-IUS users who had ovulated (n = 4) to controls, all of 
whom had ovulated. We found 1650 genes being associated with LNG-IUS use versus those in the control group 
(adjusted p-value <0.05). The decrease from the original 2509 genes is expected given the lower statistical power 
to declare significance resulting from the use of a smaller number of samples (n = 4 versus n = 11). There is an 
overlap of 1390 genes between these two sets of genes, or 84% of genes passing statistical threshold in the reduced 
number of samples were also in the original list of associated genes. The concordance is also apparent when one 
associates the estimated fold-changes of the expression of 2509 genes identified using all the data versus the esti-
mated fold-changes of expression of these genes using data for only those LNG-IUS samples who had ovulated 
(Supplemental Figure). These results indicate that lack of ovulation was not the primary driver of our results in 
the LNG-IUS group.
Effect of COC on Endometrial Gene Expression. There were 133 genes with significantly altered expres-
sion (adjusted p ≤ 0.05) in COC users compared to control samples; the top 50 genes are shown in Table 4 and the 
complete gene list is provided in Supp Table 3. The Reactome pathway categories that are altered in COC users 
are shown in Table 3 and indicate that the differentially expressed genes mapped predominantly onto pathways 
involving metal ions and acyl chain remodeling. A complete list of pathways that showed altered expression with 
a combined score >5 is shown in Supp Table 4.
Discussion
Our results demonstrate that of the three contraceptive methods examined in this study, the LNG-IUS had the 
strongest effect on the endometrial transcriptome, resulting in significant alterations in genes regulating immune 
and inflammatory pathways. These results validate findings previously published by our group in an independent 
set of samples from LNG-IUS users7. We performed the present study in part to test the hypothesis that different 
types of IUDs, as foreign bodies in the uterus, would elicit common changes in the endometrium. Instead, we 
found that the LNG-IUS resulted in differential expression of 2509 genes, whereas the cu-IUD group showed 
no effect. This unexpected finding suggests that the predominant driver of the inflammatory signal we observed 
with LNG-IUS is due to the locally released LNG, and is not a result of a foreign body per se. Previous work has 
demonstrated that LNG is implicated in oxidative stress and apoptosis, which could contribute to the effects we 
observed on the endometrial transcriptome21,22. To avoid measuring perturbations resulting from the insertion 
Levonorgestrel-releasing intrauterine system versus 
control P value Z score
Combined 
score
Immune system 2.91E-34 −2.23 172.37
Hemostasis 1.27E-18 −2.14 88.2
Cytokine signaling in Immune system 2.15E-16 −2.39 86.11
Innate immune system 1.51E-18 −2.4 82.05
Platelet activation, signaling and aggregation 9.94E-14 −2.12 63.48
Interferon signaling 7.82E-14 −2.07 62.46
Adaptive immune system 8.64E-12 −2.22 56.43
Interferon gamma signaling 1.40E-13 −1.74 51.35
Immunoregulatory interactions between a lymphoid and 
a non-lymphoid cell 4.04E-12 −1.95 51.26
Generation of second messenger molecules 1.23E-10 −1.89 43.22
Combined oral contraceptives versus control
Metallothioneins bind metals 7.37E-19 −1.85 77.15
Response to metal ions 7.37E-19 −1.8 75.23
Metabolism 8.92E-07 −2.23 31.05
Acyl chain remodeling of phosphatidylcholine 5.31E-04 −1.88 14.19
Acyl chain remodeling of phosphatidylinositol 4.60E-03 −1.86 10.03
O-linked glycosylation of mucins 8.74E-03 −2.02 9.58
Acyl chain remodeling of phosphatidylserine 5.19E-03 −1.73 9.1
Synthesis and interconversion of nucleotide di-and 
triphosphates 1.11E-02 −1.94 8.75
Diseases associated with glycosaminoglycan metabolism 1.20E-02 −1.9 8.41
Acyl chain remodeling of phosphatidylethanolamine 9.42E-03 −1.79 8.36
Table 3. Pathway categories showing altered expression from Reactome 2016 presented hierarchically by 
combined score values.







MT2A metallothionein 2A −2.404 7.33E-05
MT1M metallothionein 1M −3.467 7.33E-05
MT2A metallothionein 2A −2.198 9.04E-05
MT1JP metallothionein 1J, pseudogene −2.030 0.0002
MT1A metallothionein 1A −2.232 0.0002
S100P S100 calcium binding protein P −3.685 0.0002
MT1F metallothionein 1F −2.747 0.0003
MT1X metallothionein 1× −2.371 0.0003
DHCR24 24-dehydrocholesterol reductase −1.716 0.0003
MT1L metallothionein 1L (gene/pseudogene) −3.102 0.0003
MT1HL1 metallothionein 1H-like 1 −1.798 0.0003
ATRNL1 attractin like 1 1.713 0.0003
MT1G metallothionein 1G −3.451 0.0003
MT1B metallothionein 1B −1.394 0.0003
SLC30A2 solute carrier family 30 member 2 −1.450 0.0008
MT2A metallothionein 2A −1.604 0.0010
MFSD4A major facilitator superfamily domain containing 4A −1.938 0.0016
MT1H metallothionein 1H −3.206 0.0023
MT1E metallothionein 1E −2.243 0.0024
AIMP1 aminoacyl tRNA synthetase complex interacting multifunctional protein 1 −1.801 0.0024
FABP5 fatty acid binding protein 5 −1.497 0.0024
FABP5 fatty acid binding protein 5 −1.521 0.0024
SLC5A1 solute carrier family 5 member 1 −1.797 0.0025
PLXNC1 plexin C1 1.353 0.0025
SFN stratifin −0.995 0.0026
CATSPERB cation channel sperm associated auxiliary subunit beta −2.608 0.0029
AVPR1A arginine vasopressin receptor 1A 1.407 0.0031
ANXA2 annexin A2 −1.079 0.0031
TMEM154 transmembrane protein 154 −2.000 0.0036
STEAP1 STEAP family member 1 −1.471 0.0039
BNC2 basonuclin 2 1.362 0.0046
PLA2G2A phospholipase A2 group IIA −2.489 0.0047
DEPDC1B DEP domain containing 1B −1.692 0.0055
LURAP1L leucine rich adaptor protein 1 like −1.026 0.0063
ESR1 estrogen receptor 1 1.401 0.0065
OTUB2 OTU deubiquitinase, ubiquitin aldehyde binding 2 −0.776 0.0077
TRIM5 tripartite motif containing 5 0.731 0.0088
TC2N tandem C2 domains, nuclear −1.493 0.0088
L3MBTL3 l(3)mbt-like 3 (Drosophila) 0.828 0.0111
GPX1 glutathione peroxidase 1 −1.019 0.0127
ZNF750 zinc finger protein 750 −1.564 0.0128
CAPZA2 capping actin protein of muscle Z-line alpha subunit 2 −1.309 0.0129
MMP7 matrix metallopeptidase 7 3.066 0.0134
DPP6 dipeptidyl peptidase like 6 1.668 0.0141
LPCAT2 lysophosphatidylcholine acyltransferase 2 1.134 0.0141
CPED1 cadherin like and PC-esterase domain containing 1 1.230 0.0141
PRELP proline and arginine rich end leucine rich repeat protein 0.801 0.0141
ACACB acetyl-CoA carboxylase beta 0.558 0.0147
FXYD3 FXYD domain containing ion transport regulator 3 −1.294 0.0147
RHPN2 rhophilin Rho GTPase binding protein 2 −1.396 0.0147
Table 4. Top 50 differentially expressed genes in endometrial biopsies from COC users compared to controls 
presented hierarchically by adjusted P value.
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itself, participants were required to have had the IUD for ≥6 months, thus we do not think the transcriptional 
differences are related to length of use of the device. Previous morphological analyses demonstrated that cu-IUDs 
cause a foreign body reaction and leukocyte infiltration in the endometrium23,24; the fact that we did not see this 
effect in the global endometrial transcriptome could be due to our analysis sampling a larger surface area of the 
uterine cavity and containing both endometrium and stroma, which might have blunted the ability to detect the 
local effect seen previously on immunohistochemistry.
A prior analysis of endometrial RNA expression in users of an inert IUD demonstrated 147 genes that were 
significantly dysregulated in the first month after IUD insertion25, whereas our study showed no significantly 
differentially expressed genes in cu-IUD users with a median use of 23 months. Their study looked at Lippes 
loop IUD, not cu-IUD; the length of IUD exposure was longer in our study, and hence the effects they observed 
might be attenuated over time; and the statistical methods used to analyze gene expression were different. In our 
study, samples from both the control and the cu-IUD groups were obtained in the mid-luteal phase as confirmed 
by timing the sample collection 7–11 days after the LH surge and by serum progesterone levels >2 ng/ml at the 
time of sample collection. Our results suggest that the effects of the cu-IUD on the endometrial transcriptome are 
subtle and might be dominated by the progesterone effects of the luteal phase.
The effect of COCs on the endometrial transcriptome was intermediate between the cu-IUD and the 
LNG-IUS. Unlike the LNG-IUS, COCs did not cause changes in inflammatory pathways, however both the 
LNG-IUS and COCs caused significant downregulation of several members of the metallothionein (MT) 
gene family. MT has well-documented roles in binding of heavy metals including copper for homeostasis and 
detoxification, and is increasingly being recognized for its role in immunomodulation, apoptosis and the stress 
response26,27. Exposure to LNG-IUS in women with endometrial hyperplasia resulted in decreased immuno-
histochemical detection of MT protein28, consistent with our results showing down-regulation of MT RNA in 
endometrium in both LNG-exposed groups. Release of copper ions from the cu-IUD is postulated to be an 
important factor for its contraceptive efficacy through spermicidal effects but we did not observe a change in MT 
gene expression in the cu-IUD group. The effect on MT gene expression in the LNG-IUS and COC groups, and 
not in the cu-IUD group, supports a common effect of LNG on the endometrium in users of LNG-containing 
contraceptives related to the stress response functions of MT genes.
In our previous work, we reported 23 genes with altered expression in cervical biopsies from controls com-
pared to LNG-IUS users7, whereas in this study we found no significant differences in the cervical transcriptomes. 
The low number of differentially expressed genes and low fold-change in expression levels (maximum of 2.4-fold) 
in the prior study indicated a relatively weak effect of LNG-IUS on the cervix7. We attribute our inability to rep-
licate this finding in the current study to the differences in the statistical methods used including methods for 
normalization, for comparisons of gene expression, and adjustment for false discovery rate.
This work has several strengths. The parallel processing of samples from 4 groups of women provided a direct 
comparison of contraceptive transcriptomes that to our knowledge has not previously been performed. In cycling 
women, we synchronized collection to the mid-luteal phase to limit the effects of cyclical hormonal variation on 
our assays, and to compare contraceptive effects on the endometrial environment at the time of implantation. The 
rigorous methodology for statistical comparison of gene expression resulted in the detection of robust differences 
between the groups. Our study also has limitations. The control group was older than the other groups, resulting 
in adjustment for age in the analysis. Our sample sizes were relatively small, which may have limited our ability 
to demonstrate more subtle differences between some of the groups. We were unable to time sample collection 
precisely in the menstrual cycle in women on LNG-IUS because the majority of cycles were anovulatory, although 
our sensitivity analysis indicated that ovulatory status did not affect the results. The failure to find differences 
between the cervical transcriptomes could be due to the timing of sample collection in the luteal phase, when the 
hormonal and/or contraceptive effects would be predicted to be have produced unfavorable mucus in all groups. 
Finally, the cu-IUD is not a perfect comparator to the LNG-IUS: the ideal comparison would be the same IUD 
with and without LNG, and an ideal comparator to the LNG-IUS group would be locally applied rather than sys-
temic LNG. Nevertheless, our findings, particularly with respect to differences in IUD groups, indicate a strong 
effect of local LNG on gene expression in the endometrium.
In summary, our results demonstrate that the LNG-IUS and cu-IUD differ significantly in their effects on the 
endometrial transcriptome. Whereas the LNG-IUS induces many changes in immune and inflammatory genes 
and pathways, endometrium from cu-IUD users is indistinguishable from the luteal phase endometrium in the 
control group. These results suggest the presence of a foreign body per se has less effect on the endometrium than 
locally released LNG and argue against a foreign body reaction as a common mechanism of action of IUDs.
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